Full-Time

Capital Specialist

Sports

Posted on 9/24/2025

Deadline 10/2/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$77k - $124.2k/yr

+ Annual Performance Bonus

Boston, MA, USA + 8 more

More locations: Washington, DC, USA | Tampa, FL, USA | Miami, FL, USA | Philadelphia, PA, USA | Charlotte, NC, USA | Bridgewater, MA, USA | Hartford, CT, USA | Atlanta, GA, USA

Hybrid

Field-based role available in all major cities within the eastern part of the US. Candidates from any location are invited to apply.

Category
Sales & Account Management (1)
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree from an accredited university/college AND 1 year of professionally relevant experience
  • Associates Degree AND 3 years relevant experience (Orthopedic Sales or disciplines focused on clinical/surgical/EMT/Nursing/Physical Therapy/Rehabilitation, other patient focused field/Hospital environments or equivalent)
  • 5 years or relevant experience in lieu of education requirement
  • Certified Surgical Technician, or highly specialized selling / medical training or certification (e.g. Medical Sales College)/medical training or certification (such as in the areas of sports or athletic training/physical therapy/rehabilitation) AND 2 years of relevant work experience
  • Recently transitioned from Active Duty Military
  • The ability to work in a lab/operating room environment
  • A valid driver's license issued in the United States
  • The ability to travel which may include weekend and/or overnight travel
  • Residence in or ability to relocate to the assigned territory
  • Strong interpersonal communication, negotiation, influencing, critical thinking and problem solving skills required
  • Experienced in data analysis and have excellent problem-solving skills
  • Results orientation/sense of urgency – ability to drive to tight timelines
  • Internal and external customer focus
  • Ability to work independently and autonomously
  • Ability to work in matrix and team structure
  • High level of attention to detail
  • Proven track record of understanding, interpreting, communicating and working in a complex environment
  • Understanding of human anatomy and physiology
  • Strong technical product knowledge of surgical instruments, procedures, protocols and solutions preferred
  • Required to work in a clinical setting near radiation equipment, ability to lift 50 lbs. and wear protective gear (i.e. lead aprons)
  • Ability to travel 50-75% of the time
Responsibilities
  • Assist client’s sales organization in supporting Capital Equipment product conversions with new customers, while retaining and supporting further penetration with existing customers
  • Assist in the attainment of established sales goals including market share and business execution objectives in prescribed territory
  • Apply knowledge of sales process, product portfolio and customer knowledge to improve sales outcomes
  • Guide and assist surgeons in the operating room through their clinical and Capital Equipment product knowledge
  • Use his / her product knowledge to present, demonstrate, and ensure accurate utilization of client’s products
  • Supporting customers by attending surgeries, assuring that the proper equipment is available and performing
  • Troubleshoot and provide other technical assistance; handle customer and Surgical Sales team requests, provide in-services and training, perform field upgrades and equipment service
  • Share key customer, procedural and marketplace insights with other sales, clinical, marketing and strategic account teams to improve on solutions / service levels
  • Prepare sales reports and documents as required
  • Provide Operating Room and Sterile Processing Department consultation
  • Maintenance, tracking and effective deployment of equipment, and assets throughout assigned area ensuring product availability
  • Ensure all promotional materials are maintained in a presentable manner
  • Ensure client’s services and offering meet the highest quality standards
  • Know and follow all laws and policies that apply to one's job, and maintain the highest levels of integrity, ethics and compliance at all times
  • Analyze product performance and gain insights around engagements in customer facilities focused on optimizing the performance of products (both capital and consumables products), as well as optimize environments in which our products are used
  • Focus on customer satisfaction and retention; and improving the customers’ insights into client’s tangible and non-tangible value proposition and solutions
  • Differentiate products versus competition by providing the customer unique insights
  • Participate and support in the commercialization / implementation of client’s new products and solutions with customer
Desired Qualifications
  • Strong technical product knowledge of surgical instruments, procedures, protocols and solutions preferred

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE